Formulation Design and Characterization of an Elementary Osmotic Pump Tablet of Flurbiprofen

References

1. 1.↵
   1. Verma R. K.,
   2. Garg S.

   Current status of drug delivery technologies and future directions. Pharmaceut. Technol. On-Line 2001, 25 (2), 1–14.

   OpenUrl
2. 2.↵
   1. Verma R. K.,
   2. Divi M. K.,
   3. Garg S.

   Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Controlled Release 2002, 79 (1), 7–27.

   OpenUrlPubMed
3. 3.↵
   1. Conley R.,
   2. Gupta S. K.,
   3. Sathyan G.

   Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr. Med. Res. Opin. 2006, 22 (10), 1879–1892.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Rathbone M. J.,
   2. Handgraft J.,
   3. Roberts M. S.

   1. Wong P. S. L.,
   2. Gupta S. K.,
   3. Stewart B. E.

   Osmotically Controlled Tablets. In Modified-Release Drug Delivery Technology, Rathbone M. J., Handgraft J., Roberts M. S. , Eds.; Marcel Dekker, Inc.: New York, pp 101–114.
5. 5.↵
   1. Santus G.,
   2. Baker R. W.

   Osmotic drug delivery: a review of the patent literature. J. Controlled Release 1995, 35 (1), 1–21.

   OpenUrl
6. 6.↵
   1. Theeuwes F.

   Elementary osmotic pump. J. Pharm. Sci. 1975, 64 (12), 1987–1991.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Swanson D. R.,
   2. Barclay B. L.,
   3. Wong P. S. L.,
   4. Theuwes F.

   Nifedipine gastrointestinal therapeutic system. Am. J. Med. 1987, 83 (6), 3–9.

   OpenUrlPubMed
8. 8.↵
   1. Wong P. S. L.,
   2. Barclay B. L.,
   3. Deters J. C.,
   4. Theeuwes F.

   Osmotic Device for Administering Certain Drugs. U.S. Patent 4,765,989, 1986.
9. 9.↵
   1. Grundy J. S.,
   2. Foster R. T.

   The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties Clin. Pharmacokinet. 1996, 30 (1), 28–51.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Geerke J. H.

    Method and Apparatus for Forming Dispenser Delivery Ports. U.S. Patent 5,658,474, 1997.
11. 11.↵
    1. Herbig S. M.,
    2. Cardinal J. R.,
    3. Korsmeyer R. W.,
    4. Smith K. L.

    Asymmetric membrane tablet coating for osmotic drug delivery. J. Controlled Release 1995, 35 (2), 127–136.

    OpenUrl
12. 12.↵
    1. Chiou W. L.,
    2. Riegelman S.

    Pharmaceutical application of solid dispersion systems. J. Pharm. Sci. 1971, 60 (9), 1281–1302.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Okimoto K.,
    2. Rajewski R. A.,
    3. Stella V. J.

    Release of testosterone from an osmotic pump tablets utilizing (SBE) 7m-β-CD as both a solubilizing and an osmotic pump agent. J. Controlled Release 1999, 58 (1), 29–38.

    OpenUrlPubMed
14. 14.↵
    1. Marsh C. C.,
    2. Schuna A. A.,
    3. Sundstorm W. R.

    A review of selected investigational nonsteroidal antiinflammatory drugs of the 1980s. Pharmacotherapy 1986, 6 (1), 10–25.

    OpenUrlPubMed
15. 15.↵
    1. Thaller V. T.,
    2. Kulshrestha M. K.,
    3. Bell K.

    The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatation. Eye 2000, 14 (4), 642–645.

    OpenUrlPubMed
16. 16.↵
    1. Kanagale P.,
    2. Patel V.,
    3. Venkatesan N.,
    4. Jain M.,
    5. Patel P.,
    6. Misra A.

    Pharmaceutical development of solid dispersion based osmotic drug delivery system of nifedipine. Curr. Drug Deliv. 2008, 5 (4), 306–311.

    OpenUrlPubMed
17. 17.
    1. Mehramizi A.,
    2. Asgari M. E.,
    3. Pourfarzib M.,
    4. Bayati K. H.,
    5. Dorkoosh F. A.,
    6. Rafiee-Tehrani M.

    Influence of β-cyclodextrin complexation on lovastatin release from osmotic pump tablets. DARU J. Pharm. Sci. 2007, 15 (2), 71–78.

    OpenUrl
18. 18.↵
    1. Mehramizi A.,
    2. Alijani B.,
    3. Pourfarzib M.,
    4. Dorkoosh F. A.,
    5. Tehrani M. R.

    Solid carriers for improved solubility of glipizide in osmotically controlled oral drug delivery system. Drug Dev. Ind. Pharm. 2007, 33 (8), 812–823.

    OpenUrlPubMed
19. 19.↵
    1. Shah T. J.,
    2. Amin A. F.,
    3. Parikh J. R.,
    4. Parikh R. H.

    Process optimization and characterization of poloxamer solid dispersions of a poorly water-soluble drug. AAPS PharmSciTech 2007, 8 (2), E1–E7.

    OpenUrl
20. 20.↵
    1. Lu E. X.,
    2. Jiang Z. Q.,
    3. Zhang Q. Z.,
    4. Jiang X. G.

    A water-insoluble drug monolithic osmotic tablet system utilizing gum Arabic as an osmotic, suspending and expanding agent. J. Controlled Release 2003, 92 (3), 375–382.

    OpenUrlPubMed
21. 21.↵
    1. Chauhan C. S.,
    2. Choudhury P. K.

    Controlled porosity osmotic pump for the delivery of flurbiprofen. Curr. Drug Deliv. 2006, 3 (2), 193–198.

    OpenUrlPubMed
22. 22.↵
    1. Philip A. K.

    Osmotically regulated flow of flurbiprofen through in situ formed asymmetric membrane capsule. Curr. Drug Deliv. 2008, 5 (2), 127–132.

    OpenUrlPubMed